Diabetes is associated with increased risk of hepatocellular carcinoma in patients with cirrhosis from nonalcoholic fatty liver disease

Yang, Ju Dong, Ahmed, Fowsiyo, Mara, Kristin C., Addissie, Benyam D., Allen, Alina M., Gores, Gregory J., Roberts, Lewis R.·2020·Hepatology
DOI 10.1002/hep.30858

Cited by (209)

Items 101–200 of 209

  1. The Clinical Value of Postoperative Transarterial Chemoembolization for Resectable Patients with Intermediate Hepatocellular Carcinoma After Radical Hepatectomy: a Propensity Score-Matching Study
    Lei Wang, Chunhong Xiao, Ren Wang, Jingbo Chen, Weiping Zhou, Jingfeng Liu, Nanping Lin, Kongying Lin · 2020 · Journal of Gastrointestinal Surgery
  2. GPM6A expression is suppressed in hepatocellular carcinoma through miRNA-96 production
    Zong-Rui Li, Gang Xu, Liuyan Zhu, Hui Chen, Ji‐Min Zhu, Jian Wu · 2022 · Laboratory Investigation
  3. ONBLR: An effective optimized ensemble ML approach for classifying liver cirrhosis disease
    Dhanalaxmi Badvath, M. Aruna Safali, Sai chaitanya Kumar Gunupudi, Parish venkata Kumar Kuricheti · 2024 · Biomedical Signal Processing and Control
  4. Geriatric nutritional risk index as a prognostic factor in patients with hepatocellular carcinoma following transarterial chemoembolization: A retrospective study
    Youjiao Si, Xu Peng, Aihua Xu, Peiyuan Wang, Kaikai Zhao · 2022 · Medicine
  5. Simple proxies of insulin resistance identify obese metabolic dysfunction‐associated fatty liver disease subjects with advanced liver disease
    Giovanni Petralli, Antonio Salvati, Domenico Tricò, Gabriele Ricco, Piero Colombatto, Maurizia Rossana Brunetto, Anna Solini · 2023 · Diabetes/Metabolism Research and Reviews
  6. Hepatocellular carcinoma in patients with metabolic dysfunction-associated fatty liver disease: Can we stratify at-risk populations?
    E Fassio, Fernando Javier Barreyro, M Soledad Pérez, Diana Dávila, Graciela Landeira, Gisela Gualano, Gabriela Ruffillo · 2022 · World Journal of Hepatology
  7. NAFLD‐Related Hepatocellular Carcinoma and the Four Horsemen of the Apocalypse
    José Daniel Debes, André Boonstra, Robert Jacobus de Knegt · 2020 · Hepatology
  8. MASH to cirrhosis: bridging the gaps in MASLD management
    Zouhir Gadi, Wilhelmus Josephus Kwanten, Luisa Vonghia, Sven Francque · 2024 · Acta Clinica Belgica
  9. Diabetes and Metabolic Dysfunction–associated Steatotic Liver Disease in Adults: A Clinical Practice Guideline
    James Kim, HARPREET SINGH BAJAJ, Alnoor S. Ramji, Chantal Bémeur, Giada Sebastiani · 2025 · Canadian Journal of Diabetes
  10. Risk factors of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: Systematic review and meta-analysis
    Huimin Yin, Zhanjie Yan, Fangcheng Zhao · 2024 · Technology and Health Care
  11. Visit-to-Visit Fasting Glucose Variability in Young Adulthood and Nonalcoholic Fatty Liver Disease in Middle Age
    Haobin Zhou, Xianghui Zeng, Yuting Xue, Xiao Wang, Shenrong Liu, Zongyuan Zhu, Zichao Luo, Zhuang Ma, Hao Zhang, Qiong Zhan et al. · 2022 · The Journal of Clinical Endocrinology & Metabolism
  12. Higher Risk of Tumor Recurrence in NASH-Related Hepatocellular Carcinoma Following Curative Resection
    Shih-Chieh Chien, Yih‐Jyh Lin, Chun‐Te Lee, Yen‐Cheng Chiu, Tsung-Ching Chou, Hung‐Chih Chiu, Hung‐Wen Tsai, Che-Min Su, Tsung-Han Yang, Hsueh‐Chien Chiang et al. · 2022 · Viruses
  13. Efficacy and safety of GLP-1 receptor agonists in MASH with fibrosis: A systematic review and meta-analysis
    Rafael dos Santos Borges, Eliabe Silva de Abreu, Giovanni Gosch Berton, Luiza Haikal de Paula, Ana Flávia Conegundes, Jefferson Manoel Borges Martins, Marcelo Albuquerque Barbosa Martins, Aladdin Dahbour, Matheus Vanzin Fernandes, Manal F. Abdelmalek · 2025 · JHEP Reports
  14. HCC in metabolic syndrome: current concepts and future directions
    Lucia Zampaglione, Jacopo Ferrari, Federica Pedica, Nicolas Goossens · 2021 · Hepatoma Research
  15. Knockdown of Sirt1 Gene in Mice Results in Lipid Accumulation in the Liver Mediated via PGC-1α-Induced Mitochondrial Dysfunction and Oxidative Stress
    Hao Yang, Yuanhua Liu, Y. Wang, Shunliang Xu, D. Su · 2021 · Bulletin of Experimental Biology and Medicine
  16. Rewriting the MASLD ‐associated hepatocellular carcinoma script: Targeting epigenetics and metabolism
    Chiara Aiello, Éric Felli, Teresa Musarra, Lorenzo Nevi, Annamaria Altomare, Jordi Gracia‐Sancho, Andrea Baiocchini, Simone Carotti · 2025 · International Journal of Cancer
  17. Guía de práctica clínica multidisciplinar de manejo de la esteatosis hepática metabólica
    Manuel Romero‐Gómez, Javier Escalada, Mar Noguerol, Antonio Pérez, Juana Carretero, Javier Crespo, Juan J Mascort, Ignacio Aguilar, Francisco José Tinahones, Pedro Cañones et al. · 2025 · Gastroenterología y Hepatología
  18. Pathogenesis and management of metabolic dysfunction-associated steatohepatitis-related hepatocellular carcinoma: a narrative review
    Han Ah Lee · 2024 · Ewha Medical Journal
  19. Diabetes and the liver
    Ebo Dadey, TY Lim, Janine Makaronidis · 2025 · Clinical Medicine
  20. Diabetes and cancer: glucose control impact on survival and tumor outcomes
    Rosaria Maddalena Ruggeri, Erika Maria Grossrubatscher, Giulia Arrivi, Eleonora Ciocca, Alessia Filice, Bianca Golisano, Rossella Mazzilli, Natalie Prinzi, Annamaria Colao, Antongiulio Faggiano et al. · 2026 · Reviews in Endocrine and Metabolic Disorders
  21. Association of Diabetes Mellitus with All-Cause and Cause-Specific Mortality among Patients with Metabolic-Dysfunction-Associated Fatty Liver Disease: A Longitudinal Cohort Study
    Yixuan Zhu, Chuan Liu, Xiaoming Xu, Xiaoyan Ma, Jiacheng Liu, Zhiyi Zhang, Fuchao Li, Danny K.-H. Wong, Zhiwen Fan, Chao Wu et al. · 2023 · Journal of Personalized Medicine
  22. Current Challenges and Future Direction in Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease
    George T. Cholankeril, Hashem B. El‐Serag · 2022 · Seminars in Liver Disease
  23. The Growing Landscape of NAFLD-Associated Hepatocellular Carcinoma and Its Impact in Surveillance
    Mariana Verdelho Machado · 2023 · GE Portuguese Journal of Gastroenterology
  24. Immunotherapy as a Complement to Surgical Management of Hepatocellular Carcinoma
    Susan J. Kim, Kaelyn C. Cummins, Allan Tsung · 2024 · Cancers
  25. RISK FACTORS FOR HEPATOCELLULAR CARCINOMA IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
    Lourianne Nascimento Cavalcante, Maria Gabriela Fernandes Dezan, Cláudio Luiz da Silva Lima Paz, André Didier Lyra · 2022 · Arquivos de Gastroenterologia
  26. Letter to the Editor: Hepatocellular Carcinoma Risk in Patients With Nonalcoholic Steatohepatitis Cirrhosis and Diabetes: Insufficient for Individual Management
    Zhichao Feng, Pengfei Rong, Wei Wang · 2020 · Hepatology
  27. Inverse association between serum lipid profiles and hepatocellular carcinoma risk: a meta-analysis of epidemiological studies
    C. Zeng, Shuran Liu, Haining Li, Xiao Wei Han · 2025 · Frontiers in Oncology
  28. Addressing the essentials of the recent guidelines for managing patients with metabolic dysfunction-associated steatotic liver disease
    Dimitrios S. Karagiannakis, Katerina Stefanaki, Stavroula Α. Paschou, Μargarita Papatheodoridi, Sotirios Tsiodras, Νικόλαος Παπάνας · 2024 · HORMONES
  29. Cardiovascular events and incident diabetes in 220 patients with MASLD according to basal liver fibrosis: a 10-year follow-up historic cohort
    Cinthia Choque Vargas, Francisco Cáceres, Graciela Landeira, Soledad Perez, Laura Marchi, Gabriela Ruffillo, Silvina Tevez, Miguel Puga‐Tejada, E Fassio · 2025 · European Journal of Gastroenterology & Hepatology
  30. Impact of metabolic dysfunction-associated fatty liver disease on survival outcomes in patients undergoing radical resection for hepatitis B virus-related hepatocellular carcinoma
    Ke-Gong Xiong, Tai-Shun Lin, Qing-Biao Lin, Jinfeng Kong, Kun-Yu Ke · 2025 · Scientific Reports
  31. Joint association of physical activity and the geriatric nutritional risk index with survival outcomes among cancer survivors in the United States: a population-based cohort study
    Jing Wei, Qingyue Zeng, Ming Liu · 2024 · Frontiers in Nutrition
  32. Diabetes is associated with increased risk of hepatocellular carcinoma in non-alcoholic steatohepatitis with cirrhosis—implications for surveillance and future pharmacotherapy
    Michael Patrick Johnston, Janisha Patel, Christopher D. Byrne · 2020 · HepatoBiliary Surgery and Nutrition
  33. The antitumor effects of metformin are potentially mediated through LPA receptor inhibition
    Kōichi Sato, Hideaki Ogasawara, Yuichi Ikeda, Hidetoshi Kumagai, Ryota Inoue, Takahiro Tsuno, Koichi Matsunaga, Emi Ishida, Jun Shirakawa · 2025 · Diabetes Research and Clinical Practice
  34. Does Type 2 Diabetes Increase the Risk of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease Patients: A Systematic Review
    Sathish Venugopal, Ravneet K Dhanoa, Tharun Yadhav Selvamani, Shoukrie I Shoukrie, Anam Zahra, Jyothirmai Malla, Ramaneshwar Selvaraj, Ranim K Hamouda, Lubna Mohammed · 2023 · Cureus
  35. An integrative view on glucagon function and putative role in the progression of pancreatic neuroendocrine tumours (pNETs) and hepatocellular carcinomas (HCC)
    Bárbara Ferreira, Adrián Heredia, Jacinta Serpa · 2023 · Molecular and Cellular Endocrinology
  36. Fatty Liver Index Dynamics as a Predictor of Hepatocellular Carcinoma in Patients with Type 2 Diabetes Mellitus and Non-Cirrhotic Livers
    Eun-Hee Cho, Min Gu Kang, Chang Hun Lee, Shinyoung Oh, Chen Shen, Ha Ram Oh, Young Ran Park, Hyun Jung Lee, Jong Seung Kim, Ji Hyun Park · 2025 · Endocrinology and Metabolism
  37. Lymphocyte-to-C Reactive Protein Ratio is an Independent Predictor of Survival Benefits for Hepatocellular Carcinoma Patients Receiving Radiotherapy
    Zhan Shi, Sihui Zhu, Yuncheng Jin, Qi Liang, Mingzhen Zhou, Ziyan Zhou, Juan Zhang, Baorui Liu, Jie Shen · 2024 · Journal of Hepatocellular Carcinoma
  38. Antioxidant effects of a novel pioglitazone analogue (PA9) in a rat model of diabetes: Modulation of redox homeostasis and preservation of tissue architecture
    Neda Shakour, Mohammad Reza Mahdinezhad, Fereshteh Asgharzadeh, Majid Khazaei, Luis E. Simental‐Mendía, Nema Mohamadian Roshan, Amirhossein Sahebkar, Farzin Hadizadeh · 2024 · Journal of Diabetes and its Complications
  39. Worse survival of hepatocellular cancer patients with membranous insulin receptor overexpression
    Steffen Markus Heckl, Carolin Schneider, Lukas Kercher, Hans‐Michael Behrens, Jan-Paul Gundlach, A Bernsmeier, Stephan Schmidt, Sandra Krüger, Felix Braun, Rainer Günther et al. · 2025 · Scientific Reports
  40. Effect of Nonalcoholic Fatty Liver Disease and Metabolic Risk Factors on Waitlist Outcomes in Patients With Hepatocellular Carcinoma
    Kelley M. Weinfurtner, Jennifer L. Dodge, Francis Y. Yao, Neil J. Mehta · 2020 · Transplantation Direct
  41. Attribution of diabetes to the development of severe liver disease in the general population
    Miika Vuorinen, Ville Männistö, Veikko V Salomaa, Annie R Britton, Antti Jula, Satu Männistö, Annamari Lundqvist, Markus Perola, Fredrik O. Åberg · 2022 · Liver International
  42. Nonalcoholic Fatty Liver Diseases in Newly Analyzed Diabetes Mellitus Patients with Risk Factors
    Ayzaz Ismail, Jahangir Anjum, Hammad Ur Rehman Bhatti, Mazhar Ali Bhutto, Muhammad Azam, Ayesha Masood · 2022 · Pakistan Journal of Medical and Health Sciences
  43. Use of Metformin and Survival in Patients with Hepatocellular Carcinoma (HCC) Undergoing Liver Directed Therapy: Analysis of a Nationwide Cancer Registry
    Kumar Mukherjee, Mohammad Elsayed, Eshani J. Choksi, Mohammed F. Loya, Richard Duszak, Mehmet Akce, Bill Saliba Majdalany, Zachary Louis Bercu, Mircea M. Cristescu, Nima Kokabi · 2023 · CardioVascular and Interventional Radiology
  44. Risk of Liver Cancer in MASLD: Role of Genetic Risk Scores
    Cláudia Maccali, Isabel Veloso Alves Pereira, José Tadeu Stefano, Claudia Pinto Marques Souza de Oliveira · 2023 · Current Hepatology Reports
  45. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: diagnostic and therapeutic aspects. Review
    T. М. Bentsa · 2023 · Modern Gastroenterology
  46. Dietary Rhythms and MASLD-Related Hepatocellular Carcinoma
    Nadia Malakmahmoudi, Roberta Pisu, Ezio Laconi, Fabio Marongiu · 2024 · Cancers
  47. Disease Progression for Histologic Diagnosis of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Real-World: A Nationwide US Study
    Xinrong Zhang, Leslie Yeeman Kam, Scott Douglas Barnett, Linda L Henry, Ramsey C Cheung, Mindie H. Nguyen · 2024 · Digestive Diseases
  48. Elevated platelet distribution width and diabetes may serve as preoperative predictors of microvascular invasion in primary hepatocellular carcinoma
    Ling Wang, Liu Jun, Jia Jian’an, Rao Chunmei, Jiang Yuhuan, Peng Liu, Huiming Li · 2025 · Journal of Cancer Research and Clinical Oncology
  49. Liver transplantation for NASH-related hepatocellular carcinoma versus non-NASH etiologies of hepatocellular carcinoma: A systematic review and meta-analysis
    Kunlin Chen, Ming Jun Yang, Guangjun Li, Wentao Wang · 2025 · PLoS ONE
  50. Predictive value of thyroid-stimulating hormone in postmenopausal type 2 diabetes mellitus patients with normal thyroid function associated with ultrasound-diagnosed non-alcoholic fatty liver disease
    Yijun Du, Tianrong Pan, Xing Zhong, Nina Liu, Qiu Zhang · 2022 · All Life
  51. Epidemiology of hepatocellular carcinoma in metabolic liver disease
    Stefano Bellentani · 2020 · Hepatoma Research
  52. Risk Factor Analysis and Prevalence of the Non-Alcoholic Fatty Liver Disease in Patients with Type-II Diabetes Mellitus
    Sami Ullah, Amjad Ali, Mohammad Abu Hanif, Arjun Kumar, Hafiz Ud Din, Roomisa Anis · 2022 · Pakistan Journal of Medical and Health Sciences
  53. An Algorithmic Approach to NAFLD Screening: From PCP to Specialist
    Hirsh D. Trivedi · 2020 · ACG Case Reports Journal
  54. Triptolide Reduces Neoplastic Progression in Hepatocellular Carcinoma by Downregulating the Lipid Lipase Signaling Pathway
    Wei Chang, Jingjing Wang, Yuanqi You, Hongqian Wang, Shendong Xu, Stephen Vulcano, Changlu Xu, Chenlin Shen, Zhi Li, Jie Wang · 2024 · Cancers
  55. Reducing complications of metabolic dysfunction–associated steatotic liver disease
    Naohiro Wada, Michihiro Iwaki, Takashi Kobayashi, Atsushi Nakajima, Masato Yoneda · 2025 · Expert Review of Gastroenterology & Hepatology
  56. Multidisciplinary clinical practice guideline on the management of metabolic hepatic steatosis
    Manuel Romero‐Gómez, Javier Escalada, Mar Noguerol, Antonio Pérez, Juana Carretero, Javier Crespo, Juan José Mascort, Ignacio Aguilar, Francisco José Tinahones, Pedro Cañones et al. · 2025 · Gastroenterología y Hepatología (English Edition)
  57. Development and validation of machine learning models for diagnosing hepatocellular carcinoma risk and survival in patients with diabetic cirrhosis
    Guoqing Jiang, Wenjuan Cai, Xiuming Lv, Guixia Meng, Minghong Chen, Ling Yang, F Liu, Qingru Cao, Wenbo Chen, Juan Qian et al. · 2026 · Scientific Reports
  58. Liver Stiffness Measurement and All-Cause Mortality in Individuals With Diabetes
    Fernando Bril, Ky Huynh, P. Bolla · 2026 · JAMA Network Open
  59. Impact of cardiometabolic criteria on the pathogenesis of MASLD and diagnostic performance of non-invasive tests
    Kazuhito Kawata, Hirokazu Takahashi, Taeang Arai, Yuya Seko, Takeshi Chida, Hidenao Noritake, Hidenori Toyoda, Hideki Hayashi, Kanji Yamaguchi, Michihiro Iwaki et al. · 2026 · Journal of Gastroenterology
  60. Metabolically associated fatty liver disease: What hepatologists need to know about this systemic disease
    Alexander L. PLAKIDA, Ольга Юшковська, Lidia Elżbieta Sierpińska · 2026 · World Journal of Hepatology
  61. Incidence, Predictors, and Course of Hepatocellular Carcinoma Following Direct-Acting Antivirals Therapy in a Prospective Genotype-3 Predominant HCV Elimination Compensated Cirrhosis Cohort
    Madhumita Premkumar, Prerna Sharma, Pankaj C. Gupta, Anchal Sandhu, Harish Bhujade, Radhika Srinivasan, Arka De, Nipun Verma, Ajay Kumar. Duseja, Sreedhara Bettadahally Chaluvashetty et al. · 2026 · Journal of Clinical and Experimental Hepatology
  62. The molecular mechanism on the association of diabetes mellitus with hepatocellular carcinoma
    Wanming Zheng, Minghua Deng, Jianping Gong · 2020 · International Surgery Journal
  63. Liver Cancer - Genesis, Progression and Metastasis
    Mark A. Feitelson, Alla L. Arzumanyan · 2022 · IntechOpen eBooks
  64. Hepatitis Viruses: Hepatocellular Carcinoma
    Danbi Lee, Ju Dong Yang, Roongruedee Chaiteerakij, Lewis Rowland Roberts · 2023 · Springer eBooks
  65. Characterization of the modulatory effect of zeaxanthin isolated from maize kernels on cellular signaling pathways associated with hyperglycemia-induced HepG2 cell proliferation
    Tehreem Maradagi, Nimish Mol Stephen, Ravi Kumar, Numbi Ramudu Kamini, Ganesan Ponesakki · 2024 · PharmaNutrition
  66. Effects of weight loss from oral semaglutide administration on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a retrospective analysis using propensity score matching
    Kazuki Aoyama, Yuya Nakajima, Shu Meguro, Kaori Hayashi · 2024 · Diabetology International
  67. Caracterización de la enfermedad hepática crónica, cirrosis y progresión a carcinoma hepatocelular en una entidad promotora de salud en Colombia: estudio retrospectivo de diez años
    Joshua Kock, Juan Felipe Betancur, Jhon Edwar Bolaños-López, Luz Eugenia Pérez, Carlos José Bello-Gándara, Farley Johanna González-Patiño, José Sanabria Vanegas, José David Manga-Peña, Carlos Andrés Badillo-Blanco · 2025 · Hepatología
  68. Diagnosis and treatment of metabolic dysfunction-associated fatty liver disease -related hepatocellular carcinoma
    Ke-Gong Xiong, Tai-Shun Lin, Qing-Biao Lin, Jinfeng Kong, Kun-Yu Ke · 2025 · Egyptian Liver Journal
  69. The impact of diabetes and social, biologic and behavioral determinants of health on liver cancer risk
    Marwa Shouman, Ayad A. Jaffa, Miran A. Jaffa · 2025 · Frontiers in Endocrinology
  70. Diabetes und Gastroenterologie – Update 2021
    Jörg Bojunga, A. Beckerbauer · 2021 · Der Diabetologe
  71. The Role of Senescence in NASH-Related HCC
    Lampros Chrysavgis, Grigorios Papadopoulos, Antonios Chatzigeorgiou · 2022 · Interdisciplinary cancer research
  72. NAFLD et NASH au cours du diabète : données épidémiologiques, cliniques et pronostiques
    Sarah Béland‐Bonenfant, Jean‐Michel Petit, Bruno L Vergès · 2023 · Médecine des Maladies Métaboliques
  73. Type 2 Diabetes Mellitus and Insulin Resistance in Nonalcoholic Fatty Liver Disease
    Cătălina Mihai, Bogdan Mircea Mihai, Cristina Cijevschi Prelipcean · 2023 · Springer eBooks
  74. Factores de riesgo de fibrosis avanzada en enfermedad hepática esteatósica asociada a disfunción metabólica en pacientes con diabetes mellitus 2
    Gonzalo Miranda, Herman Vildozola G. · 2023 · Revista de Gastroenterología del Perú
  75. Food Insecurity is Associated with Nonalcoholic Fatty Liver Disease, Cognitive Impairment, and Immune Activation in People Living with HIV
    Javier A. Tamargo · 2021
  76. Investigating the impact of concurrent type 2 diabetes on the occurrence of liver cancer in 2501 patients with chronic hepatitis B
    Changxiang Lai, Xiulian Zhang, Wenjie Xian, Wenqing Zhong, Qiyuan Tang, Zhiyu Li, Xuan Zhou, Ruikun Chen, Qingrong Tang, Fang Wang · 2024 · Research Square
  77. Corrigendum. Guía de práctica clínica multidisciplinar de manejo de la esteatosis hepática metabólica
    Manuel Romero-Gómez, Javier Escalada, Mar Noguerol, Antonio Pérez, Juana Carretero, Javier Crespo, Juan J Mascort, Ignacio Aguilar, Francisco Tinahones, Pedro Cañones et al. · 2026 · Gastroenterología y Hepatología
  78. Letter to the Editor: The Association Between Diabetes and Hepatocellular Carcinoma in Patients With Cirrhosis Caused by Nonalcoholic Fatty Liver Disease
    Xinxing Tantai, Na Liu, Jinhai Wang · 2020 · Hepatology
  79. Reply
    Ju Dong Yang, Kristin C. Mara, Gregory James Gores, Lewis Rowland Roberts · 2020 · Hepatology
  80. Alcohol Consumption in Non-Alcoholic Fatty Liver Disease: Safety and Disease Overlap
    Sheela S. Reddy · 2020 · Current Hepatology Reports
  81. Risk Factors of Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
    Wenpei Guo, Lixin Liu · 2021 · Research Square
  82. Ribonucleic acid sequence analysis in deciphering hepatocellular carcinoma
    Sravanthi Mannem, Muralidhar Yegireddy, Narayanan Krishnaswamy, Bala Prabhakar Girish, Prakash Nadoor · 2022 · Elsevier eBooks
  83. Identification of a hub gene in hepatocellular carcinoma induced by nonalcoholic fatty liver disease using bioinformatics analysis
    Juan Li, Chutian Wu, Xiongxiu Liu, Linjing Long, Lixian Zhong, Junlong Lai, Junqin Lin, Yuting Li, Qiuting Zeng, Shaohui Tang · 2022 · Research Square
  84. REPLY:
    Ju Dong Yang, Kristin C. Mara, Gregory James Gores, Lewis Rowland Roberts · 2020 · Hepatology
  85. Incidence and Type II Diabetes Mellitus Risk Factors in Chronic Hepatitis Type C Affected Patients
    Kuldeep Kumar Poorani, Muhammad Amjad Kalhoro, Atif Ali Ahmed, Kashif Ali, Safia Bano, Bedar, Bakhat Khan · 2022 · Pakistan Journal of Medical and Health Sciences
  86. Hepatocellular Carcinoma and Diabetes
    Sunanda Gupta, Manya Prasad, Archana Ramalingam · 2022 · Scholars Journal of Applied Medical Sciences
  87. Pathophysiology and Diagnosis of Chronic Liver Disease
    Aisha Shabbir, Misbah Arshad, Ali Junaid Dar, Sidra Khalid · 2021 · Pakistan Journal of Health Sciences
  88. Glycemic control, body weight reduction, or glucose-lowering therapy in diabetic patients: What is better for the liver?
    Salvatore Petta · 2023 · Nutrition Metabolism and Cardiovascular Diseases
  89. Non-alcoholic Fatty Liver Disease Associated Hepatocellular Carcinoma
    Kai Sun, Alan Wade Hodges, Maen Abdelrahim · 2023 · IntechOpen eBooks
  90. Gene trail of polarized M2 macrophage decodes tumor heterogeneity and recommendation for therapy of hepatocellular carcinoma
    Minjie Zhao, Changlin Tang, Hang Liang, Xinyu Sun, Kun Wu · 2024 · Research Square
  91. LIRIC predicts Hepatocellular Carcinoma risk in the diverse U.S. population using routine clinical data
    Kai Jia, Bowen Gu, Pasapol Saowakon, Steven Kundrot, Matvey B. Palchuk, Jeff Warnick, I.D. Kaplan, Martin Rinard, Limor Appelbaum · 2024 · medRxiv
  92. Risk Stratification of Metabolic Risk Factors and Statin Use Associated With Liver and Nonliver Outcomes in Chronic Hepatitis B
    Xinrong Zhang, Vy H. Nguyen, Leslie Yeeman Kam, Scott Douglas Barnett, Linda L Henry, Ramsey C Cheung, Mindie H. Nguyen · 2024 · The Journal of Infectious Diseases
  93. Metabolic Dysfunction-associated Steatotic Liver Disease–related Hepatocellular Carcinoma: Current Research Insights
    Ho Soo Chun, Minjong Lee, Tae Hun Kim · 2024 · Journal of Digestive Cancer Research
  94. Hepatic Satellite Cell Activation and Alteration of Vitamin A Status Are Relevant to the Aggravation of Retinopathy by T2DM
    Min-Chun Chang, David Pei‐Cheng Lin, Han‐Hsin Chang · 2025 · Investigative Ophthalmology & Visual Science
  95. Evaluation of Glycated Hemoglobin Levels in Cirrhotic Patients Across Different Child-Pugh Classes
    Rabia Qayoom Shaikh, Mukhtair Hussain Jafferi, Abdul Ghaffar Daras, Sobia Karamullah, Fouzia Shaikh, Imran Shaikh · 2025 · Pakistan Journal of Health Sciences
  96. GLP-1 RECEPTOR AGONISTS IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: THERAPEUTIC POTENTIAL AND CLINICAL CHALLENGES
    Michał Bzoma, Hubert Bochenek, Paweł Kamiński, Irmina Czerepak, Julia Gugulska, Anna Bielicka, Tomasz Szwarc, Mateusz Kałwik, Karolina Niewczas, Adrianna Brzozowska · 2025 · International Journal of Innovative Technologies in Social Science
  97. Bibliometric Analysis of Emerging Trends and Hotspots in the Links between Nonalcoholic Steatohepatitis and Diabetes Mellitus from 2004 to 2023
    Chen Xie, Tao Liu, Yuanxin Zhong, Zhengyu Li, Ji Xu, Zijun Zhao, Xinqiang Wang, Po Gao · 2025 · Endocrine Metabolic & Immune Disorders - Drug Targets
  98. Additional file 2 of Identification of metabolic biomarkers associated with nonalcoholic fatty liver disease
    Jiang, Hua, Hu, Yang, Zhang, Zhibo, Xujia Chen, Gao, Jianpeng · 2024 · Figshare
  99. Additional file 1 of Identification of metabolic biomarkers associated with nonalcoholic fatty liver disease
    Jiang, Hua, Hu, Yang, Zhang, Zhibo, Xujia Chen, Gao, Jianpeng · 2024 · Figshare
  100. Corrigendum. Multidisciplinary clinical practice guideline on the management of metabolic hepatic steatosis
    Manuel Romero-Gómez, Javier Escalada, Mar Noguerol, Antonio Pérez, Juana Carretero, Javier Crespo, Juan J Mascort, Ignacio Aguilar, Francisco Tinahones, Pedro Cañones et al. · 2026 · Gastroenterología y Hepatología (English Edition)